Headache in Behcet’s disease: types and characteristics

Maryam Moghaddassi1, Mansoureh Togha2,3*, Farhad Shahram1, Hamed Hanif4, Sahar Dadkhah5, Soodeh Razeghi Jahromi6 and Mohammad Mozafari2

Abstract

Background: Behcet’s disease involves several systems in the body. Neurological involvement is identified by different symptoms. Headache is one of the common complaints of patients with Behcet’s disease. It might be a part of neurological involvement or may arise independently in the course of disease. Studies with small sample size have resulted in various findings in this field. Since the prevalence of Behcet’s disease is relatively high in Iran, this study was carried out to compare the features of headache between an acceptable number of patients with this rare disease and a control group.

Methods: The current case–control study was performed to compare the features of headache between 312 patients with definite Behcet’s disease who referred to a Behcet’s clinic and healthy individuals. Patients with Behcet’s disease were randomly selected. Controls were matched for age and sex. They were personally examined and interviewed meticulously using a questionnaire that met the standards of the International Headache Society classification for different types of headache.

Results: The incidence of headache in the case and control groups was 28.3 % (n = 120) and 18.6 % (n = 59), respectively (p < 0.05; OR 2.73). Tension-type headache was observed in 12.2 % (n = 38) of cases which was significantly higher than control group (n = 6.3 %) (p = 0.011; OR 2.05). The most frequent type of headache in the case group was tension-type headache (12.2 %). In the control group, however, migraine without aura was the most common type (9.1 %). A correlation between ophthalmological involvement and headache was observed in 11 patients in the case group. In addition, a significantly higher systolic blood pressure was found in the case group compared to the controls (125.1 vs. 121.7 mmHg; p = 0.007). There was no major correlation between prednisolone consumption in patients with Behcet’s disease and the type and frequency of headache.

Conclusions: Headache, especially tension-type headache, is more common in patients with Behcet’s disease. This might be the result of specific types of uveitis-related and non-structural headaches seen in Behcet’s disease.

Keywords: Behcet’s disease, Headache, Migraine, Non-structural headache
eye lesions, and a positive pathergy test (Weichsler et al. 1990). In addition to these common features that confirm the diagnosis, BD contains minor manifestations like joint involvement, disorders of large vessels, and gastrointestinal, pulmonary, cardiac, and neurological syndromes. Among all neurological symptoms in BD, headache is the most frequent (Borhani Haghighi et al. 2005).

Headache occurrence in patients with BD might indicate onset of neuro-BD (NBD); however, the majority of these headaches are benign (Fountain and Dhurandhar 2014). Occasionally, BD is misdiagnosed as aseptic meningitis, multiple sclerosis, or a primary neoplasm (Fountain and Dhurandhar 2014). Although the prevalence of headache in BD is so high that some studies do not consider it as a sign for neurological involvement, it remains as a major complaint of many patients (Weichsler et al. 1990; Borhani Haghighi et al. 2005). In fact, the rate of neurological involvement varies from 2.5 to 49 % in different studies since some of them do not consider headache as a neurological symptom of BD (Weichsler et al. 1990; Borhani Haghighi et al. 2005). There are many untested theories concerning higher prevalence of specific types of headache in patients with BD (Davatchi et al. 2010; Monastero et al. 2003). For instance, a study in Iran illustrated that 57 % of patients experience tension-type headaches while 28.5 % complain from migraine. This study also mentioned an association between headaches and attacks of oral ulcers in about 12 % and uveoretinitis in 1.5 % of BD patients. However, it did not point out any significant difference between the cases and general population (Sikaroodi et al. 1992). Another questionnaire-based British study revealed the prevalence of recurrent headache to be 82.5 % in BD, with the dominant features of migraine headache pertaining to most headaches (Kidd 2003). Moreover, a separate prevalence study demonstrated a significantly higher frequency of migraine without aura in patients with BD (Monastero et al. 2003).

Specific types of headache which cannot be classified as primary and secondary and emerge in the course of BD are called “non-structural headaches of BD”. The prevalence of these types of headaches in BD shows notable variation among different studies (Sakane et al. 1999). Many of the previous studies in this field have focused on the characteristics and specific treatments of headache in BD disease and all have reached challenging results (Monastero et al. 2003; Sikaroodi et al. 1992; Kidd 2003). Considering the disparities seen between previous investigations and high prevalence of BD in Iran, this study was designed to further delve into the frequency and characteristics of headache in BD with a larger number of cases.

**Methods**

The current study was a case–control study performed at the multidisciplinary BD outpatient clinic. The total sample size was 629 (cases plus controls). For almost 4 months, all of the patients admitted to the BD outpatient clinic were consecutively included in the case group. In order to match the case and control groups in terms of socioeconomic characteristics, individuals in the control group were selected from patients in urology and orthopedic clinics of another hospital over a period of almost 5 months and matched for age and sex.

**Case group**

The inclusion criterion was a definite diagnosis of BD and patients who did not agree to take part in this study were excluded. The diagnosis of BD was certain in patients in the case group, according to the BD classification criteria of the International Study Group. The patients were randomly selected and interviewed regardless of how long they have been diagnosed with BD. Each patient was individually interviewed and examined. A 2-part questionnaire was used for interviews. The first part included demographic information and general settings of the disease focusing on the clinical course of BD. The second part includes the headache characteristics according to the International Classification of Headache Disorders, second edition (ICHD-2) (2004) and the time relations between headache occurrence and first symptoms of BD. A trained general physician interviewed the patients and filled the questionnaire.

Primary headaches were classified as migraine with aura, migraine without aura, tension-type headaches, and cluster headaches. In accordance with a Turkish study, headaches that started 6 months before the onset of BD or any other headaches occurring after the onset of the disease which did not meet the criteria of international headache society (IHS) for primary headaches were classified as non-structural headaches related to BD (Tursen et al. 2003). Any headache along with neurological symptoms (except for classic associating symptoms of primary headaches) according to ICHD-2 was considered as NBD. After being confirmed by an ophthalmologist, severe localized headaches occurring during uveitis attacks were regarded as uveitis-related headaches.

For patients obtaining the characteristics of more than one specific type of headache, the most severe and classified one according to the criteria was investigated. For example, when a combination of a headache secondary
to neurological involvement and any other type of head-
ache was present, the first one was considered as the main
headache. Patients who had any other clinical findings that
could be related to other types of secondary headaches
were referred for further investigation. When the proper
diagnosis was made, the headaches were classified as one
of the secondary types of headache such as headaches due
to infections and sinusitis. Patients with reliable med-
ical documents confirming their underlying disease that
caused headaches were not sent for further evaluation.

Control group
Subjects in the control group were selected from patients,
without BD, who were based in urology and orthopedic
clinics in another hospital. The control group included
age- and sex-matched subjects for individuals in the case
group. Each person filled the aforementioned question-
naire except for the part referring to the duration and
onset of BD. Individuals that had any head and neck
injury or any other internal disease that could be the rea-
son of their headaches were excluded.

Data analysis
Statistical package for the social sciences (SPSS) soft-
ware for windows version 19.0 (IBM Inc., New York, NY,
USA) was used to carry out the statistical analyses. In this
analysis, $\alpha = 0.05$ and $\beta = 0.1$. Also, 11 % difference in
headache prevalence between the two groups was con-
sidered. The sample size was calculated to be at least 297
in each group. We used student’s t test for comparison of
quantitative data and Chi square test for comparison of
qualitative data. Moreover, $P$ values less than 0.05 were
considered significant.

Ethical considerations
Patients voluntarily participated in this study. Their par-
ticipation did not interfere with their normal treatment
procedure. All of the patients provided written informed
consents. Also, the ethics committee of Tehran Univer-
sity of Medical Sciences approved this study.

Results
This study was performed on 312 (139 females and
173 males) patients in the case group and on 317 (138
females and 179 males) age- and sex-matched con-
trols (Table 1). Both groups were similar in terms of
sex distribution ($p = 0.7$). The mean age of participants
was 39 years in both groups. The mean duration of BD
was $10.3 \pm 7.63$ years in the case group. The mean sys-
tolic blood pressure was significantly different between
the case and control groups (125.1 vs. 121.7 mmHg;
$p = 0.007$) (Table 1).

Our study revealed that the disease-related prevalence
of headache was higher among patients with BD. The
total prevalence of different types of headache was 28.3
and 18.6 % in the case and control groups, respectively.
Tension-type headache was the most common type of
headache in the case group with the prevalence of 12.2 %.
However, the most common type of headache among
the control group was migraine without aura with the
prevalence of 9.1 %. It is noteworthy that the frequency of
tension-type headache was significantly higher in female
patients with BD ($p = 0.002$). There was no report of
cluster headache or other autonomic neuralgias in either
case or control groups (Table 2).

While headaches secondary to ophthalmological
involvement were found in 11 (3.5 %) patients with BD,
10 patients had anterior uveitis. As Table 3 shows, there
was a significant association between headache presence
and only one BD manifestation and that manifestation
was anterior uveitis ($p = 0.025$). Moreover, 15 patients
(4.8 % of patients with BD) were suffering from non-
structural headaches related to BD. However, there was
no statistically significant correlation between this type
of headache and severity ($p = 0.170$), quality ($p = 0.082$),
and clinical course of BD ($p = 0.089$). All of these patients

Table 1 Age, systolic blood pressure and sex of participants in case and control groups

|                      | Mean          | Medium       | Minimum       | Maximum       | 95 % CI         | P value |
|----------------------|---------------|--------------|---------------|---------------|-----------------|---------|
|                      | Case | Control | Case | Control | Case | Control | Case | Control | Case | Control |
| Age (years)          | 39.63 | 39.12 | 39  | 39  | 15  | 15  | 74  | 73  | 38.33–40.93 | 37.81–40.43 | 0.953 |
| Blood pressure (mmHg)| 125.1 | 121.7 | 125 | 120 | 90  | 90  | 170 | 160 | 123.2–126.9 | 120.3–123.1 | 0.007 |

| Sex                  |               |               |               |               |                 |         |
|----------------------|---------------|--------------|---------------|---------------|-----------------|---------|
|                      | Case | Control | Case | Control | Case | Control | Case | Control |
| Male                 | 173  | 179     | 138 | 139     | 173 | 179     |      |         |
| Female               | 139  |         |      |         |      |         |      |         |

CI: confidence interval
had normal magnetic resonance imaging (MRI) results and thus, were not diagnosed with NBD.

Interestingly, 15 patients with BD who did not suffer from headaches at the time of the study and were consequently not considered as cases of headache in the current study were found to have had a history of neurological involvement in the course of their BD. To be more precise, seven patients had a history of appropriately treated cerebral venous sinus thrombosis, four other patients were identified to have a history of brain stem involvement, three others had brain parenchymal lesions and another patient developed Behcet’s meningoencephalitis, as the primary presentation of BD, which was fully treated and did not recur.

The onset of headache was found to be years after the onset of BD in 58% of patients. On the contrary, 20% of the patients recalled having headaches years before they were diagnosed with BD. Moreover, 22% of the cases reported the onset of headaches to be simultaneous or within 6 months of BD diagnosis. The association between the onset of BD and timing of headaches was not statistically significant ($p = 0.069$).

Consumption of medications was another issue of interest. According to the performed analyses, the prevalence of headaches was not significantly different between patients who received prednisolone at a dose of 7.5 mg/kg daily and those who did not consume prednisolone. On the other hand, although the prevalence of headache was about 2 times higher in patients receiving 7.5 mg/kg daily and more (32.5 vs. 67%), this difference was not statistically significant ($p = 0.10$).

Some patients of both the case and control groups (about 15%) received specific treatment for their headaches and the two groups were not significantly different in this regard (Table 4).

In addition, headache frequency was not significantly associated with human leukocyte antigen (HLA) B51, HLA B5, and positive pathergy test ($p = 0.15, 0.57$, and $0.99$, respectively).

The number of individuals with a positive family history of headache, especially migraine and tension-type headache, was not significantly different between the

### Table 2 Frequency and types of headaches in case and control groups

|                          | Case (n = 312) | Control (n = 317) | Odds ratio | 95 % CI | P value |
|--------------------------|---------------|-------------------|------------|--------|---------|
| Overall frequency of headaches, n (%) | 120 (38.3 %)  | 59 (18.6 %)       | 2.73       | 1.9–3.9 | >0.01   |
| Migraine with aura, n (%)   | 12 (3.8 %)    | 8 (2.5 %)         | 1.5        | 0.6–3.8 | 0.345   |
| Migraine without aura, n (%) | 35 (11.2 %)   | 29 (9.1 %)        | 1.2        | 0.7–2.01 | 0.391   |
| Tension-type headache, n (%) | 38 (12.2 %)   | 20 (6.3 %)        | 2.05       | 1.17–3.62 | 0.011   |

CI: confidence interval

### Table 3 Manifestations of Behcet’s disease and correlations with headache

| Behcet’s disease symptoms | Overall | Headache | P value |
|---------------------------|---------|----------|---------|
|                          | +       | −        |         |
| Anterior uveitis          | 152     | 89       | 63      | 0.025   |
|                          | –       | 160      | 104     | 56      |
| Posterior uveitis         | 188     | 116      | 72      | 0.944   |
|                          | –       | 124      | 77      | 47      |
| Retinal vasculitis        | 151     | 99       | 52      | 0.192   |
|                          | –       | 161      | 94      | 67      |
| Macular edema             | 19      | 9        | 10      | 0.180   |
|                          | –       | 293      | 184     | 109     |
| Decrease of visual acuity | 45      | 24       | 21      | 0.203   |
|                          | –       | 267      | 169     | 98      |
| Genital aphthous          | 175     | 104      | 71      | 0.318   |
|                          | –       | 137      | 89      | 48      |
| Erythema nodosum          | 77      | 52       | 25      | 0.238   |
|                          | –       | 235      | 141     | 94      |
| Pseudofolliculitis        | 124     | 83       | 41      | 0.134   |
|                          | –       | 188      | 110     | 78      |
| Cellulitis                | 1       | 1        | 0       | 0.432   |
|                          | –       | 311      | 192     | 119     |
| Vasculitis                | 2       | 2        | 0       | 0.265   |
|                          | –       | 310      | 191     | 119     |
| Aneurysm                  | 1       | 1        | 0       | 0.432   |
|                          | –       | 311      | 192     | 119     |
| Arthritis                 | 140     | 82       | 58      | 0.582   |
|                          | –       | 171      | 110     | 61      |
| Superficial and deep phlebitis | 17   | 15       | 2       | 0.451   |
|                          | –       | 294      | 177     | 117     |
| Central nervous system involvement | 16 | 11       | 5       | 0.553   |
|                          | –       | 195      | 181     | 114     |
| Seizure                   | 6       | 5        | 1       | 0.272   |
|                          | –       | 305      | 187     | 118     |
| Meningoencephalitis       | 1       | 1        | 0       | 0.432   |
|                          | –       | 311      | 192     | 119     |
| Involvements of other organs | 10    | 4        | 6       | 0.148   |
|                          | –       | 310      | 189     | 113     |

P values with italic font means they are significant (P values less than 0.05 were considered significant)
case and control groups \((p = 0.99)\). However, it was significantly higher in individuals complaining from headaches in each group (Table 5).

We also compared 150 normotensive BD patients to 191 controls who had normal systolic blood pressure. The rate of headache in these groups was 59 and 41 %, respectively \((p = 0.001; 95 \% \text{ confidence interval}: 1.4–3.8; \text{odds ratio} = 2.3)\).

### Discussion

BD is a multi-organ disease and the clinical features are mainly of mucocutaneous and ophthalmological origins (Davatchi et al. 2010). The most frequent early manifestations of neurological involvement in BD are gait disturbance, dysarthria, and headache (Yoon et al. 2014). As in any other population, headache is one of the most common symptoms of patients with BD. However, the prevalence of recurrent headache in BD has been estimated to be 82.5 %, with the features of migraine headache being the most dominant. In fact, headache can be a sign of neurological involvement in BD or may arise independently in the course of BD (Ashjazadeh et al. 2003).

The characteristics of primary headaches such as migraine, tension-type and cluster headaches, secondary headaches like those following ophthalmological involvement and non-structural headaches related to BD have been a field of interest in many studies. Meanwhile, the rarity and specific geographical distribution of BD have resulted in studies with small sample size. In this current, large-scale, cross-sectional study we found the overall prevalence of headache to be higher in patients with BD. Although similar to a previous study in our center, (Sikaroodi et al. 1992) the total prevalence of 28.3 % observed in our study was in contrast with studies in the United Kingdom (Kidd 2003), Italy (Monastero et al. 2003) and Turkey (Turkish Headache Epidemiology Study Group 1998), which all reported rates above 60 %.

Our study revealed tension-type headaches to be significantly more frequent among patients with BD than the control group. Sikaroodi et al. (1992) suggested similar findings. The frequency of non-structural headaches was found to be one-third of that reported in the study carried out in Turkey (Turkish Headache Epidemiology Study Group 1998). Patients with this kind of headache had a normal MRI and neither did they meet the criteria of the IHS nor had they any other underlying conditions that could be related to the headache. Additionally, we found no significant correlation between the onset of these headaches and other systemic symptoms such as aphthous ulcers.

Previous studies reported a link between blood pressure and headache (Harandi et al. 2013; Fagernaes et al. 2015). In the current study, the mean systolic blood pressure was significantly higher in patients with BD. This might be due to consumption of prednisolone or atherogenic pathologies of BD. In order to make sure that the difference in blood pressure does not cause dissimilarity in prevalence of headache among the case and control groups, we compared 150 patients with BD to 191 controls who had normal systolic blood pressure. Despite the similarity in blood pressure, the prevalence of headache was higher in BD group.

The frequency of uveitis-related headaches was found to be 3.5 % in this study, which was in agreement with other studies (Monastero et al. 2003; Kidd 2003). However, uveitis was the only symptom that established a significantly positive correlation with the general frequency of headaches in patients with BD.

The hypothesis that prednisolone reduces the prevalence of headache in BD was not confirmed in our study. This might be a result of the difference between the

---

**Table 4** Drugs used for headache in the case and control groups

| Family history, n | Frequency in case group, n (%) | Frequency in control group, n (%) | Odds ratio | 95 % CI | P value |
|-------------------|---------------------------------|-----------------------------------|------------|--------|---------|
| Family history    | Positive | Negative |                 |          |         |        |
| Headache +        | 18 (15.1 %) | 9 (15.3 %) | 0.99 | 0.4–2.3 | 0.980 |
| Headache –        | 58 (48.7 %) | 43 (72.9 %) | 0.35 | 0.18–0.69 | 0.002 |
| No treatment      | 43 (36.1 %) | 7 (11.9 %) | 4.2 | 1.7–10.0 | 0.001 |

OTC: over the counter, CI: confidence interval

---

**Table 5** Family history of headaches in the case and control groups

| Family history, n | Odds ratio | 95 % CI | P value |
|-------------------|------------|--------|---------|
| Positive | Negative |          |         |        |
| Case   | Headache + | 28 | 92 | 0.86 | 1.03–3.34 | 0.037 |
| Headache – | 27 | 165 | 2.54 | 1.32–4.88 | 0.004 |
| Control | Headache + | 18 | 41 | 2.54 | 1.32–4.88 | 0.004 |
| Headache – | 38 | 220 | 2.54 | 1.32–4.88 | 0.004 |

CI: confidence interval
generally prescribed doses of prednisolone for patients with BD and doses required for treatment of headache. Prednisolone is rarely ordered for patients with headaches that do not respond to any other treatment. The usual dosage is at least 30 mg/daily for 2 weeks. Therefore, it seems rational that the common doses of prednisolone used for treatment of BD (7.5–15 mg/daily) exert a weak effect on headaches.

In some of our cases, an association was found between history of neurological involvement of BD and headache. Headaches were completely resolved after the treatment of neurological involvement. Although there was no significant association between NBD and headache prevalence, 15 out of 16 patients with neurological involvement reported history of severe headaches before the initiation of treatment for neurological lesions. After inquiring about the history of headache at the time of the neurological involvement, the relationship was found to be significant (p = 0.0001), with an odds ratio of 1.23. These findings are consistent with previous studies considering headache as the most common symptom in NBD (Ashjazadeh et al. 2003).

While in the United Kingdom 15 % of patients with BD are referred to hospitals to receive related medicine for headaches, (Kidd 2003) the referral rate turned out to be 5 % in our study. However, other reports in the country (Iran) have estimated a rate of 15 %. Considering social facilities in Iran, good insurance coverage and different levels of referral, 15 % does not seem that remarkable.

Our study revealed that the rate of treatment by over the counter analgesics versus non-medical treatments for headaches in BD was significantly different between the case and control groups. This might be due to lack of compliance of BD patients with receiving additional medicine, ergo their higher rate of applying non-medical treatments.

To be noted, in this study we found no specific pattern for intensity, characteristics, or localization of headaches in BD patients. Perhaps larger multi-center trials in the future can reveal any possible relationships between BD severity and duration and its major and minor symptoms and the above-mentioned variables of tension-type headache and migraine and even outline potential causal/temporal correlations. This feat has been achieved for other pain and rheumatologic disorders such as fibromyalgia syndrome and temporomandibular pain disorder (Giamberardino et al. 2015; Dahan et al. 2015).

The strengths of the current study were the large randomly selected population and the use of validated diagnostic criteria for headaches. As a limitation, the study was conducted on patients in a referral center and this might have rendered a lower coverage compared to a multi-center study.

Conclusions
The overall prevalence of headache, especially tension-type headache, tends to be higher in patients with BD. Although headaches are among the most common complaints of BD patients, they are usually not appropriately considered and managed by their responsible physician.

Abbreviations
BD: Behcet’s disease; NBD: neuro-Behcet’s disease; ICHD-2: international classification of headache disorders, second edition; IHS: international headache society; SPSS: statistical package for the social sciences; MRI: magnetic resonance imaging.

Authors’ contributions
MW (Moghaddasi), MT, HH and FS jointly conceived and designed the study. HH and SD interviewed and examined the patients. MM (Moghaddasi), MT and FS supervised the medical interviews and examinations. HH and SD carried out the data analysis. MT, SD, SRJ and MM (Mozafari) drafted the manuscript. MM (Moghaddasi), MT, FS, SRJ and MM (Mozafari) critically revised the manuscript for important intellectual contents. All authors read and approved the final manuscript.

Acknowledgements
We would like to thank the staff of the multidisciplinary BD outpatient clinic, Rheumatology Research Center and Headache Research Center, all affiliated to Tehran University of Medical Sciences, for providing us with an excellent environment for research.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data will not be shared due to inadvertent deletion of datasets in the computer of the corresponding author. The mentioned datasets could not be recovered and are, unfortunately, permanently lost. We sincerely apologize for this inconvenience.

Funding
The Authors declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. This research received no specific grant from any funding agency in the commercial or not-for-profit sectors.

Ethics approval
The ethics committee of Tehran University of Medical Sciences approved this research from an ethical point of view.

Ethics, consent and permissions
We hereby declare that every single individual in this study participated on their own will and written, informed consents were obtained for this matter.

Received: 13 June 2016 Accepted: 30 June 2016 Published online: 13 July 2016
References

Ashjazadeh N, Borhani Haghighi A, Samangoogie S, Moosavi H (2003) Neuro-Behçet’s disease: a masquerader of multiple sclerosis. A prospective study of neurologic manifestations of Behçet’s disease in 96 Iranian patients. Exp Mol Pathol 74(1):17–22

Borhani Haghighi A, Pourmand R, Nikseresht AR (2005) Neuro-Behçet disease. In: Borhani Haghighi A, Pourmand R, Nikseresht AR (eds) Rheumatology APLAR 1992. Churchill Livingstone Japan K.K, Tokyo, pp 107–109

Akbarian M, Gharibdoost F (2003) Recent epidemiological data on Behçet’s disease in Iran. The 2001 survey. Adv Exp Med Biol 528:31–36. doi:10.1007/0-306-48382-3_5

Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291. doi:10.1056/nejm199910213411707

Shahram F, Davatchi F, Nadji A, Jamshidi A, Chams H, Chams C, Shafaie N, Akbarian M, Gharibdoost F (2003) Recent epidemiological data on Behçet’s disease in Iran. The 2001 survey. Adv Exp Med Biol 528:31–36. doi:10.1007/0-306-48382-3_5

The international classification of headache disorders. 2nd edition (2004). Cephalalgia 24(Suppl 1):9–160

Turkish Headache Epidemiology Study Group (1998) An epidemiologic study of headache in Turkey: a nationwide survey. Neurology 50(1):156–162. doi:10.1016/ene.12547(e110–151)

Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42(5):346–351

Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, Yazici H, Barnes CG, Chamberlain MA, James DG, Lehner T (1990) Criterions for diagnosis of Behçet’s disease. International Study Group for Behçet’s disease. Arthritis Rheum 34(17):1284–1291. doi:10.1007/0-306-48382-3_5

Yoon DL, Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B (2014) Neuro-beehet’s disease in South Korea: clinical characteristics and treatment response. Int J Rheum Dis 17(4):425–431. doi:10.1111/i1756-185X.2014.01254.x

Zhang Z, PENG J, HOU X, DONG Y (2006) Clinical manifestations of Behçet’s disease in Chinese patients. APLAR J Rheumatol 9:244–247. doi:10.1016/j.aplr.2005.12.002

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at springeropen.com